
Opinion|Videos|January 31, 2025
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience
2
Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis
3
Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control
4
Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year
5























